Biofortuna Limited, a laboratory services and contract development and manufacturing organization (CDMO), has completed its acquisition of Cryoniss Ltd, a company specializing in biological sample storage, including ultra-low and cryogenic temperatures for long-term sample preservation. This acquisition emphasizes Biofortuna’s commitment to supporting transformative research and development in the biotech and life sciences industries. By integrating Cryoniss’s expertise and infrastructure, Biofortuna enhances its stability storage capabilities and propels the expansion of its controlled-environment storage services. Cryoniss provides critical services for a range of applications such as academic research, drug discovery, and diagnostic test development. Biofortuna CEO, Dr. Nick Ash, stated that the acquisition creates a perfect synergy with their current services, offering comprehensive solutions to clients from sample storage to analytical services. The merge promises to deliver an integrated end-to-end service for customers looking for single-site provision. Sonia Houghton, CEO of Cryoniss, expressed that the acquisition by Biofortuna opens up new opportunities, enabling broader exposure to markets in the life sciences and biotech sectors, while providing quick and efficient access to Cryoniss’s highly accredited services.

Biotechnology & Life Sciences,Global